Document Classification

Section Type: RESULTS

Text: Although total (6. 5 vs. -6. 7 %, P < 0. 0001) and low-density lipoprotein (LDL) (8. 6 vs. -9. 1 %, P = 0. 004) cholesterol increased significantly in the abacavir/lamivudine group relative to the tenofovir/emtricitabine group, we found no significant changes in the biomarkers : CRP (-3. 9 vs. 0. 0 %), MCP-1 (5. 9 vs. 4. 0 %), osteoprotegerin (5. 1 vs. -2. 8 %), IL-6 (0. 0 vs. 0. 0 %), IL-10 (0. 0 vs. 0. 0 %), TNF-alpha (0. 0 vs. 0. 0 %), ICAM-1 (6. 6 vs. 5. 2 %), VCAM-1 (0. 02 vs. -0. 01 %), selectin E (-0. 4 vs. 7. 8 %), selectin P (4. 6 vs. 12. 6 %), insulin (-2. 5 vs. 8. 8 %), adiponectin (-2. 2 vs. 15. 4 %), and D-dimer (0. 0 vs. 0. 0 %) (P > or = 0. 12 for all comparisons).